Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Other Operating Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Operating Expenses for 9 consecutive years, with $249.1 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 202.25% to $249.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $481.2 million through Dec 2025, up 55.6% year-over-year, with the annual reading at $366.4 million for FY2025, 2.83% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $249.1 million at ImmunityBio, up from $87.1 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $355.1 million in Q4 2023, with the low at $681000.0 in Q4 2022.
  • Average Other Operating Expenses over 4 years is $114.6 million, with a median of $89.9 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses soared 52039.79% in 2023, then plummeted 76.79% in 2024.
  • Over 4 years, Other Operating Expenses stood at $681000.0 in 2022, then skyrocketed by 52039.79% to $355.1 million in 2023, then tumbled by 76.79% to $82.4 million in 2024, then skyrocketed by 202.25% to $249.1 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $249.1 million, $87.1 million, and $96.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.